THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Aug 26, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "THROmbinography in Pregnant Women and in Vitro Action of Low Molecular Weight Heparin," is studying how pregnancy affects blood clotting and the use of a medication called low-molecular-weight heparin (LMWH) to prevent blood clots in pregnant women. During pregnancy, women's bodies undergo significant changes that can lead to a higher risk of blood clots, especially in the legs or lungs. The researchers want to understand how LMWH works in pregnant women compared to non-pregnant women, as well as how it affects clotting during different stages of pregnancy and after childbirth.

To participate in this trial, women must be in their first trimester of a normal pregnancy and be over 18 years old. However, those with certain health conditions, such as known blood clotting disorders or a history of blood clots, cannot join. Participants will have their blood tested to measure how well it clots before and after receiving LMWH in a lab setting. This study aims to gather important information that could help doctors determine the best dose of LMWH for pregnant women to ensure their safety and well-being during and after pregnancy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Normal 1st trimester pregnancy
• • Age \> 18
• Exclusion Criteria:
• • Coagulation disease (Von Willebrand disease, known coagulation factor deficiency before pregnancy)
• • VTE history
• • First-degree family history of idiopathic VTE
• • Known biological risk factor for thrombosis Inherited deficiencies in coagulation inhibitors (antithrombin, protein C, protein S) Factor V Leiden polymorphism Prothrombin gene 20210G\>A polymorphism Anti-phospholipid antibodies
• • Current anticoagulant use (VKA, heparins, etc.)
• • Gestational diabetes detected in the 1st trimester
• • Pre-existing type 1 and type 2 diabetes
• • History of pathological pregnancy Premature delivery Postpartum hemorrhage Preeclampsia
• • Hepatopathy
• • Obesity (BMI ≥ 30)
• • Infections (HIV, HBV, HCV...)
• • Autoimmune diseases
• • Pregnancy resulting from in vitro fertilization protocol
• • Multiple pregnancy
• • Patient under guardianship, curatorship or safeguard of justice
• • Patient not covered by a social security scheme
• • Patient deprived of liberty